FDA Approves Kisqali for Early-Stage Breast Cancer
September 17, 2024
Kisqali (chemical name: ribociclib) can now be used after surgery in combination with an aromatase inhibitor to treat stage II or stage III hormone receptor-positive, HER2-negative breast cancer with a high risk of recurrence. Read more…